View More View Less
  • 1 Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi, 110062, India
Restricted access

Summary

An accurate, sensitive, precise, rapid and isocratic reversed-phase HPLC (RPHPLC) method for analysis of buspirone in the bulk drug and in solid dosage formulations has been developed and validated. The best separation was achieved on a 250 mm × 4.6 mm i.d., 5-μm particle, RP C18 column with 70:30 (υ/υ) methanol-0.01 m sodium dihydrogen phosphate buffer (pH 3.5) as mobile phase at a flow rate of 0.8 mL min−1. UV detection was at 244 nm. Response was a linear function of concentration over the range 0.05–20 μg mL−1 (r = 0.9998) and the limits of detection and quantitation were 3.7 and 11.3 ng mL−1, respectively. The method was validated in accordance with ICH guidelines. The drug was subjected to oxidative, hydrolytic, photolytic, and thermal stress. Degradation products produced as a result of this stress did not interfere with detection of buspirone and the assay can thus be regarded as stability-indicating. The method was used for quantification of buspirone in commercial buspirone tablets and to check content uniformity. The excipients present in the formulation did not interfere with the assay. The method is suitable for application in quality-control laboratories, because it is simple and rapid with good accuracy and precision.

  • [1]. A.S. Eison D.L. Temple 1986 Am. J. Med. 80 1.

  • [2]. K.L. Goa A. Ward 1986 Drugs 32 114.

  • [3]. H. Goldberg 1994 Pharmacotherapy 4 315.

  • [4]. R. Krysiak E. Obuchowicz Z.S. Herman 1986 Neur. Res. 51 924.

  • [5]. Z. Chilmonckyk H. Ksycinska J. Cybulski A. Wozniakowska-Szelejewska 1986 Die Pharm. 51 924.

  • [6]. A. Gobert A. Newman-Tancredi J.M. Rivet V. Audinot M.J. Millan 1997 Eur. Neuropyschopharmacol. 7 S149.

  • [7]. S.M. Fouroton A. Zarghi A.R. Shafaati A. Khoddam 2004 Farmaco 59 739.

  • [8]. X. Aparicio A. Campos J. Gras E. Fernandez E. Gelpi 1988 J. Pharm. Biomed. Anal. 6 945.

  • [9]. P. Betto A. Meneguz G. Ricciarello E. Fernandez C. Pichini 1992 J. Chromatogr. 575 117.

  • [10]. M. Franklin 1990 J. Chromatogr. 526 590.

  • [11]. J. Odontiadis M. Franklin 1996 J. Pharm. Biomed. Anal. 14 347.

  • [12]. W.M. Chew M.-J. Xu C.A. Cordova H.-H. Sherrychow 2006 J. Chromatogr. B 844 25.

  • [13]. S.-H. Cho H.-W. Lee H.-T. Im W.-S. Park Y.-W. Choi J.-H. Rew K.-T. Lee 2006 Rapid Commun. Mass Spectrom. 20 1293.

  • [14]. E. Nagele A.S. Fandino 2007 J. Chromatogr. A 1156 196.

  • [15]. J.W. Hager J.C. YvesLeBlanc 2003 J. Chromatogr. A 1020 3.

  • [16]. F. Kristjannson 1991 J. Chromatogr. 566 250.

  • [17]. T.H. Tsai C.F. Chen 1997 J. Chromatogr. A 762 269.

  • [18]. E.H. Kerns R.A. Routick K.J. Volk M.S. Lee 1997 J. Chromatogr. B 698 133.

  • [19]. C.A. Goldthwaite Jr F.-Y. Hsieh S.W. Womble B.J. Noves I.A. Blair 1996 Anal. Chem. 68 2996.

  • [20]. M.G. Quaglia A. Farina E. Bossu C.D. Aquila 1995 J. Pharm. Biomed. Anal. 13 505.

  • [21]. S.M. Sabry M.H. Barary M.H. Abdel Hay T.S. Belal 2004 J. Pharm. Biomed. Anal. 34 509.

  • [22]. A. Khedr A. Sekr 1999 J. Chromatogr. Sci. 37 462.

  • [23]. M. Zaxariou I. Panderi 2004 J. Pharm. Biomed. Anal. 35 41.

  • [24]. Z. Plotkowiak J. Cybulski M. Popielarz-Brzezinska A. Grzeszkiewicz I. Centrowska A. Kalska-Kowalska 1996 Chem. Anal. 41 983.

  • [25]. N. Adel-Ghani , Y. Issa, A. Shoukry, and H. Ahmed, Ann. Chim., 97 (2007).

  • [26]. J.A. Squella Y. Borges L. Bobadilla L.J. Nunez-Vergara 1990 Electroanal. J. 4 333.

  • [27]. W.M.A. Niessen J. Lin G.C. Bondoux 2002 J. Chromatogr. A 970 131.

  • [28]. R.T. Sane N.L. Chonken S.R. Surve M.G. Gangrade V.V. Bapat 1993 Indian Drugs 30 235.

  • [29]. V.C. Jacob S.N. Murthy J. Saravanan J. Ravishankar 1997 Indian Drugs 34 24.

  • [30]. International Conference on Harmonization (ICH), Validation of Analytical Procedures: Text and Methodology Q2 (R1), November 2005.

    • Search Google Scholar
    • Export Citation
  • [31]. S.C. Chow and J. Shao, Statistics in Drug Research: Methodologies and Recent Developments, Marcel Dekker, 2002, pp. 3152.

  • [32]. M. Zeaiter J.M. Roger V.B. Maurel D.N. Rutledge 2004 Trends Anal. Chem. 23 157.

  • [33]. M. Mulholland 1988 Trends Anal. Chem. 7 383.

  • [34]. ICH 2000 Stability Testing of New Drug Substances and Products (Q1AR). International Conference on Harmonisation IFPMA Geneva.

  • [35]. ICH 1999 Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. International Conference on Harmonisation IFPMA Geneva.

    • Search Google Scholar
    • Export Citation
  • [36]. International Conference on Harmonization 2003 Guidance for Industry, Q1A (R2): Stability Testing of New Drug Substances and Products IFPMA Geneva.

    • Search Google Scholar
    • Export Citation